openPR Logo
Press release

Alcohol Use Disorder Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

12-05-2024 02:06 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Alcohol Use Disorder Clinical Trials

Alcohol Use Disorder Clinical Trials

(Albany, USA) DelveInsight's, "Alcohol Use Disorder Pipeline Insight, 2024" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Alcohol Use Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

"Alcohol Use Disorder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcohol Use Disorder Market.
The Alcohol Use Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Explore our latest breakthroughs in Alcohol Use Disorder Research. Learn more about our innovative pipeline today! @ Alcohol Use Disorder Pipeline Outlook- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Alcohol Use Disorder Pipeline Report
• In November 2024:- Tempero Bio Inc.- The purpose of this study is to assess the safety, tolerability and effect on alcohol use (number of heavy drinking days) of TMP-301 compared to placebo in patients with alcohol use disorder. This is a placebo-controlled, parallel-group, multicenter clinical study in moderate to severe alcohol use disorder with ≥8 heavy drinking days over the prior 4 weeks at screening. Study participants and investigators will be blinded to study intervention. The study duration will be up to 19 weeks, with a treatment duration of up to 14 weeks. The visit frequency will be weekly.
• In November 2024:- Novo Nordisk A/S- The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
• DelveInsight's Alcohol Use Disorder pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Alcohol Use Disorder treatment.
• The leading Alcohol Use Disorder Companies such as Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, and others.
• Promising Alcohol Use Disorder Therapies such as Sunobinop, Psilocybin, CMND-100, TMP-301, Brexanolone, and others.

Stay informed about the cutting-edge advancements in Alcohol Use Disorder treatments. Download for updates and be a part of the revolution in care @ Alcohol Use Disorder Clinical Trials Assessment- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alcohol Use Disorder Emerging Drugs Profile
• AD04: Adial Pharmaceuticals
AD04, developed by Adial Pharmaceuticals, is a genetically targeted therapeutic agent designed to treat Alcohol Use Disorder (AUD). It works by modulating specific neurotransmitter pathways that are implicated in the brain's reward and reinforcement circuits related to alcohol consumption. The drug is being developed for patients with particular genetic markers, identified through a proprietary companion diagnostic genetic test, and has shown promise in reducing heavy drinking days in a subgroup of patients during a Phase III clinical trial. AD04's mechanism of action is believed to involve balancing the activity of the serotonergic and dopaminergic systems, potentially reducing alcohol cravings and consumption.

• MN-166 (ibudilast): MediciNova
MN-166 (ibudilast) portfolio, which includes the phase II-staged lead drug compound and proprietary analogs, represents novel, first-in-class, non-opioid drugs for the treatment of drug addiction, progressive multiple sclerosis and pain. MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. Ibudilast's anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical study results and provide the rationale for its therapeutic utility in neurodegenerative diseases (e.g., progressive MS and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease), substance abuse/addiction and chronic neuropathic

• BICX104: BiocorRx Pharmaceuticals
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder (OUD) being developed to improve patient compliance to naltrexone therapy compared to other marketed treatments. In Phase I, an open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the PK and safety of BICX104 and the once-a-month intramuscular naltrexone injection (Vivitrol), BICX104 was well tolerated with no serious adverse events and achieved 84 days of therapeutic naltrexone plasma concentrations. BICX104 is being developed under BioCorRx Pharmaceuticals Inc., the Company's majority-owned clinical-stage pharmaceutical subsidiary. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Alcohol Use Disorder.

Learn more about Alcohol Use Disorder Drugs opportunities in our groundbreaking Alcohol Use Disorder Research and development projects @ Alcohol Use Disorder Unmet Needs- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alcohol Use Disorder Companies
Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, and others.

Alcohol Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Alcohol Use Disorder Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Alcohol Use Disorder treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Alcohol Use Disorder Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Alcohol Use Disorder Pipeline Report
• Coverage- Global
• Alcohol Use Disorder Companies- Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, and others.
• Alcohol Use Disorder Therapies- Sunobinop, Psilocybin, CMND-100, TMP-301, Brexanolone, and others.
• Alcohol Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Alcohol Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Alcohol Use Disorder Pipeline on our website @ Alcohol Use Disorder Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Alcohol Use Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Alcohol Use Disorder- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. AD04: Adial Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MN-166 (ibudilast): MediciNova
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BICX104: BiocorRx Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Alcohol Use Disorder Key Companies
21. Alcohol Use Disorder Key Products
22. Alcohol Use Disorder- Unmet Needs
23. Alcohol Use Disorder- Market Drivers and Barriers
24. Alcohol Use Disorder- Future Perspectives and Conclusion
25. Alcohol Use Disorder Analyst Views
26. Alcohol Use Disorder Key Companies
27. Appendix

Trending Report:
• Molecular Glue Trials: https://www.delveinsight.com/report-store/molecular-glues-competitive-landscape
• Cellulitis Market: https://www.delveinsight.com/blog/acute-bacterial-skin-and-skin-structure-infection-and-current-therapeutic-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-epidemiology-forecast
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Xerostomia Market: https://www.delveinsight.com/whitepaper-newsletter/xerostomia-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/infographics/bronchopulmonary-dysplasia-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Head And Neck Squamous Cell Carcinoma Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Thrombocytopenia Market: https://www.delveinsight.com/report-store/thrombocytopenia-market
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Acute Ocular Pain And Inflammation Market: https://www.delveinsight.com/report-store/acute-ocular-pain-aop-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alcohol Use Disorder Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight here

News-ID: 3774133 • Views: …

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides…

All 5 Releases


More Releases for Alcohol

Digital Breath Alcohol Testers Market Reliable and Accurate Solutions for Alcoho …
Global Digital Breath Alcohol Testers Market Overview: The Digital Breath Alcohol Testers market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others. In recent years, the Digital Breath Alcohol Testers market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and…
Alcohol Screening Breathalyzer and Alcohol Screening Device Manufacturer | ALCOF …
ALCOFIND, a DA Tech brand, is a trustworthy and flawless maker of alcohol screening breathalyzer. It includes both an advanced alcohol tester and an alcohol screening device.  DA Tech has dedicated itself to the research and development of sensor-related application solutions since its foundation in 2002, firmly establishing itself as a specialized breathalyser company and emerging as a global leader. ALCOFIND breathalyser has quality certifications for the world's major breathalyser markets, including…
Impact of COVID-19 on Alcohol Disinfectants Market by Products (Propyl Alcohol, …
The global Alcohol Disinfectants market is one of the fastest-growing markets in the world. The following report contains all the statistics and facts & figures related to the global Alcohol Disinfectants market. Their business strategies, sales data, projections, and a host of other important data have been covered for an in-depth outlook. The report also has PEST analysis, SWOT analysis, risk analysis, and regional analysis. 3M Company, BODE Chemie Gmbh,…
Alcohol Sensor Market By Drägerwerk AG & Co. KGaA, Abbott, Alcohol Countermeasur …
Global alcohol sensor market is expected to reach USD 4.33 billion by 2026 from USD 1.55 billion in 2018 and is projected to grow at a CAGR of 13.7% in the forecast period of 2019 to 2026. Global Alcohol Sensor market research report provides a detailed synopsis on the study for market and how it is impacting the Semiconductors and Electronics industry. The key research methodology used here by DBMR team…
PRESS- Premium Alcohol Seltzer
MEDIA RELEASE CONTACT: FRANK SINGLETON frank@franksingletoncommunications.com 678.316.4237 PRESS launches premium alcohol seltzer in key US markets Regional distribution includes Chicago, Boston, Atlanta, New York, Salt Lake Milwaukee, WI—Major metropolitan locations across the country are part of a multi- region, multi-city national launch of new light-alcohol beverage brand PRESS, a fruit and spice infused alcohol seltzer being distributed in cities known as trend-forward cuisine and beverage marketplaces. Locations were selected based on market demographics including active…
Alcohol Testing Market - Increasing usage of alcohol testing devices, which are …
Alcohol testers are used to scrutinize whether an individual is under the effect of alcohol. Alcohol testing looks for traces of alcohol in a human body using samples of urine, hair, saliva, blood, breath, or sweat. Alcohol testing is an expanding market, due to the high consumption of alcohol and growth in the aging population that shows indications of increase in use of alcohol and prescription drugs. Alcohol tester is…